top of page
15775039_10154090418227761_7861539286113583910_o_10154090418227761.jpg

RESOURCES

Check out these links to learn more about psychedelic assisted therapy from experts in the field

Drug-Science-pills-scaled.jpg

DRUG SCIENCE

Psychoactive drugs expert, Prof David Nutt, promotes evidence based drug policy

HOW TO CHANGE YOUR MIND

Join journalist Michael Pollan on his journey as he explores the world of psychedelic therapy, a novice learning from the world's foremost experts and then from the plants themselves.

how to change your mind.jpg
maps-stacked-1200x630sq.jpeg

MAPS

Founded in 1986, the Multidisciplinary Association for Psychedelic Studies is a non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and cannabis.

rickTEDtalk.jpg

MAPS

Rick Doblin is the founder of Multidisciplinary Association for Psychedelic Studies.
MAPS’ Phase 3 clinical trial of MDMA-assisted therapy demonstrated statistically significant improvement in PTSD symptoms after three sessions.

maxresdefault.jpg

                                                                        TED TALK

Can Psilocybin unlock Depression?

gyfunuqvuqs7zowpjgrdbctl.png

MEDICAL PSYCHEDELICS WORKING GROUP

The Drug Science Podcast

On July 14th 2020, the UK’s leading independent scientific body on drugs has launched the Drug Science Medical Psychedelics Working Group. The Medical Psychedelics Working Group is a consortium of Drug Science experts, leading academics, researchers and policy specialists, supported by industry partners. The group’s aim is to create a rational and enlightened approach to psychedelic research and clinical treatment. The group will explore innovation within the psychedelic space with a specific focus on how psychedelics can be integrated into primary and secondary healthcare. Evidence-based science, sharing data, and strong partnerships are keys to success for the psychedelic community. The purpose of this group is to break down the barriers of 50 years of medical censorship by creating a rational and enlightened approach to psychedelic research and clinical treatment, ensuring the UK is a world leader in psychedelic medicine.

HOW PSYCHEDELICS WORK

Interview with Robin Carhart-Harris

Robin Carhart-Harris is a psychologist and neuroscientist and Head of the Centre for Psychedelic Research, Division of Brain Sciences, Faculty of Medicine at Imperial College London. He coordinated the first clinical study of psilocybin in the UK and the first clinical study of a classic psychedelic drug in the UK for over 40 years.
After being awarded an MA in Psychoanalysis at Brunel University, London, Carhart-Harris completed his PhD in psychopharmacology at the University of Bristol. In 2009, under the mentorship of Professor David Nutt, he relocated to Imperial College London to continue his fMRI research with the classic psychedelic psilocybin. In conjunction with David Nutt, he built up a program of psychedelic research that includes fMR and MEG imaging with psilocybin, fMR imaging with MDMA, and plans for an MRC-sponsored clinical trial to assess the efficacy of psilocybin as a treatment for major depression.

robin ch.jpg
bottom of page